Kronos Bio, Inc.
KRON · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $6 | $0 | $0 |
| % Growth | 56.6% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $4 | $4 |
| Gross Profit | $10 | $6 | -$4 | -$4 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $49 | $86 | $94 | $113 |
| G&A Expenses | $25 | $42 | $43 | $38 |
| SG&A Expenses | $25 | $42 | $43 | $38 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $29 | $0 | $0 | $0 |
| Operating Expenses | $103 | $128 | $137 | $151 |
| Operating Income | -$93 | -$122 | -$137 | -$151 |
| % Margin | -943.2% | -1,937.5% | – | – |
| Other Income/Exp. Net | $7 | $9 | $4 | $0 |
| Pre-Tax Income | -$86 | -$113 | -$133 | -$151 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$86 | -$113 | -$129 | -$149 |
| % Margin | -874.1% | -1,791.9% | – | – |
| EPS | -1.43 | -1.95 | -2.3 | -2.72 |
| % Growth | 26.7% | 15.2% | 15.4% | – |
| EPS Diluted | -1.43 | -1.95 | -2.3 | -2.72 |
| Weighted Avg Shares Out | 60 | 58 | 56 | 55 |
| Weighted Avg Shares Out Dil | 60 | 58 | 56 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $9 | $4 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $4 | $4 |
| EBITDA | -$62 | -$120 | -$129 | -$147 |
| % Margin | -626.7% | -1,903.5% | – | – |